weekly_roundup
BioTechSign Daily Catalyst Roundup - November 06, 2026
Top BioTechSign catalyst names today: EYPT, GRFS, NKTR, ARGX, NUVB, ALNY. FDA, clinical trial, grade-change, dilution, and sentiment signals.
BiotechSign AnalysisNovember 6, 2026
Daily Biotech Catalyst Digest: November 06, 2026
EYPT leads the current BioTechSign screen at 84.8/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.
Top Catalyst Scores
| Ticker | Company | Score | Grade | Strongest Inputs |
|---|---|---|---|---|
| EYPT | EyePoint, Inc. | 84.8 | A | clinical activity 100%, short interest 70%, dilution risk 43% |
| GRFS | Grifols SA | 74.8 | B | publication signal 100%, clinical activity 100%, dilution risk 19% |
| NKTR | Nektar Therapeutics | 74.0 | B | short interest 90%, clinical activity 75%, dilution risk 65% |
| ARGX | argenx SE | 74.0 | B | publication signal 100%, clinical activity 100%, dilution risk 15% |
| NUVB | Nuvation Bio | 73.4 | B | clinical activity 88%, PDUFA timing 75%, short interest 70% |
| ALNY | Alnylam Pharmaceuticals | 72.9 | B | publication signal 100%, clinical activity 100%, dilution risk 10% |
Recent Grade-Change Queue
- IBRX (ImmunityBio, Inc.) currently grades B with a 70.0/100 catalyst score. Main inputs: clinical activity 100%, short interest 90%, PDUFA timing 55%.
- GLUE (Monte Rosa Therapeutics) currently grades D with a 42.1/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, dilution risk 48%.
- CADL (Candel Therapeutics, Inc.) currently grades F with a 26.7/100 catalyst score. Main inputs: short interest 70%, clinical activity 38%, dilution risk 27%.
- ALNY (Alnylam Pharmaceuticals) currently grades B with a 72.9/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, dilution risk 10%.
- DYN (Dyne Therapeutics) currently grades D with a 42.2/100 catalyst score. Main inputs: publication signal 100%, clinical activity 58%, PDUFA timing 55%.
- URGN (UroGen Pharma Ltd.) currently grades F with a 27.8/100 catalyst score. Main inputs: clinical activity 54%, short interest 50%, dilution risk 45%.
- FATE (Fate Therapeutics) currently grades F with a 25.5/100 catalyst score. Main inputs: publication signal 100%, short interest 50%, dilution risk 35%.
- COGT (Cogent Biosciences) currently grades B with a 66.9/100 catalyst score. Main inputs: publication signal 100%, PDUFA timing 90%, short interest 50%.
What To Watch
Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.